Abstract
Caveolin, a major protein component of caveolae, directly interacts with multiple signaling molecules, such as Ras and growth factor receptors, and inhibits their function. However, the role of the second messenger system in mediating this inhibition by caveolin remains poorly understood. We examined the role of Ca2+ -dependent signal in caveloin-mediated growth inhibition using a rat cardiac myoblast cell line (H9C2), in which the expression of caveolin-3, the muscle specific subtype, can be induced using the LacSwitch system. Upon induction with IPTG and serum-starvation, the expression of caveolin-3 was increased by 3.3-fold relative to that of mock-induced cells. The recombinant caveolin-3 was localized to the same subcellular fraction as endogenous caveolin-3 after sucrose gradient purification. Angiotensin II enhanced ERK phosphorylation, but this enhancement was significantly decreased in caveolin-3-induced cells in comparison to that in mock-induced cells. Similarly, when cells were stimulated with fetal calf serum, DNA synthesis, as determined by [3H]-thymidine incorporation, was significantly decreased in caveolin-3-induced cells. When cells were treated with Ca2+ chelator (BAPTA and EGTA), however, this attenuation was blunted. Calphostin (PKC inhibitor), but not cyclosporine A treatment (calcineurin inhibitor), blunted this attenuation in caveolin-3 induced cells. Our findings suggest that caveolin exhibits growth inhibition in a Ca2+-dependent manner, most likely through PKC, in cardiac myoblasts.
Keywords: protein kinase C, calcineurin, H9C2 cells, caveolin-3
References
- 1.Sargiacomo M, Sudol M, Tang Z, Lisanti M. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol. 1993;122:789–807. doi: 10.1083/jcb.122.4.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Song K, Scherer P, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz D, Lisanti M. Expression of caveolin-3 in skeletal, cardia, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996;271:15160–5. doi: 10.1074/jbc.271.25.15160. [DOI] [PubMed] [Google Scholar]
- 3.Li S, Okamoto T, Chun M, Sargiacomo M, Casanova J, Hansen S, Nishimoto I, Lisanti M. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995;270:15693–701. doi: 10.1074/jbc.270.26.15693. [DOI] [PubMed] [Google Scholar]
- 4.Li S, Couet J, Lisanti M. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996;271:29182–90. doi: 10.1074/jbc.271.46.29182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Engelman J, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz D, Lisanti M. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 1998;428:205–11. doi: 10.1016/s0014-5793(98)00470-0. [DOI] [PubMed] [Google Scholar]
- 6.Toya Y, Schwencke C, Couet J, Lisanti M, Ishikawa Y. Inhibition of adenylyl cyclase by caveolin peptides. Endocrinology. 1998;139:2025–31. doi: 10.1210/endo.139.4.5957. [DOI] [PubMed] [Google Scholar]
- 7.Razani B, Zhang X, Bitzer M, Von Gersdorff G, Bottinger E, Lisanti M. Caveolin-1 regulates transforming growth factor (TGF)-β/SMAD signaling through an interaction with the TGF-β type I receptor. J Biol Chem. 2001;276:6727–38. doi: 10.1074/jbc.M008340200. [DOI] [PubMed] [Google Scholar]
- 8.Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S, Couet J, Lisanti M, Ishikawa Y. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem. 1997;272:33416–21. doi: 10.1074/jbc.272.52.33416. [DOI] [PubMed] [Google Scholar]
- 9.Park W, Cho K, Park J, Kim D, Park S. 2001. p. 928. Attenuation of EGF signaling in senescent cells by caveolin Ann N Y Acad Sci. [DOI] [PubMed]
- 10.Yamamoto M, Toya Y, Jensen RA, Ishikawa Y. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res. 1999;247:380–8. doi: 10.1006/excr.1998.4379. [DOI] [PubMed] [Google Scholar]
- 11.Molkentin J, Dorn IGn. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391–426. doi: 10.1146/annurev.physiol.63.1.391. [DOI] [PubMed] [Google Scholar]
- 12.Ostrom RS. Caveolins muscle their way into the regulation of cell differentiation, development, and function. Focus on “Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs muscle cells.”. Am J Physiol Cell Physiol. 2005;288:C507–9. doi: 10.1152/ajpcell.00531.2004. [DOI] [PubMed] [Google Scholar]
- 13.Koga A, Oka N, Kikuchi T, Miyazaki H, Kato S, Imaizumi T. Adenovirus-mediated overexpression of caveolin-3 inhibits rat cardiomyocyte hypertrophy. Hypertension. 2003;42:213–9. doi: 10.1161/01.HYP.0000082926.08268.5D. [DOI] [PubMed] [Google Scholar]
- 14.Dodge KL, Scott JD. Calcineurin anchoring and cell signaling. Biochem Biophys Res Commun. 2003;311:1111–5. doi: 10.1016/j.bbrc.2003.09.040. [DOI] [PubMed] [Google Scholar]
- 15.Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215–28. doi: 10.1016/s0092-8674(00)81573-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Taigen T, de Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA. 2000;97:1196–201. doi: 10.1073/pnas.97.3.1196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.de Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW, 2nd, Kitsis RN, Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. Circ Res. 2000;86:255–63. doi: 10.1161/01.res.86.3.255. [DOI] [PubMed] [Google Scholar]
- 18.Sabri A, Steinberg SF. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem. 2003;251:97–101. [PubMed] [Google Scholar]
- 19.Taggart MJ, Leavis P, Feron O, Morgan KG. Inhibition of PKCα and rhoA translocation in differentiated smooth muscle by a caveolin scaffolding domain peptide. Exp Cell Res. 2000;258:72–81. doi: 10.1006/excr.2000.4891. [DOI] [PubMed] [Google Scholar]
- 20.Fujita T, Toya Y, Iwatsubo K, Onda T, Kimura K, Umemura S, Ishikawa Y. Accumulation of molecules involved in α1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res. 2001;51:709–16. doi: 10.1016/s0008-6363(01)00348-0. [DOI] [PubMed] [Google Scholar]
- 21.de Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem. 2000;275:13571–9. doi: 10.1074/jbc.275.18.13571. [DOI] [PubMed] [Google Scholar]
- 22.Avraham A, Jung S, Samuels Y, Seger R, Ben-Neriah Y. Co-stimulation-dependent activation of a JNK-kinase in T lymphocytes. Eur J Immunol. 1998;28:2320–30. doi: 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
- 23.Werlen G, Jacinto E, Xia Y, Karin M. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J. 1998;17:3101–11. doi: 10.1093/emboj/17.11.3101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Levy D, Garrison R, Savage D, Kannel W, Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–6. doi: 10.1056/NEJM199005313222203. [DOI] [PubMed] [Google Scholar]